Literature DB >> 32512950

From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances.

Ikrame Zeouk1,2, Khadija Bekhti2, Jacob Lorenzo-Morales1,3.   

Abstract

The emergence of a novel human coronavirus (SARS-CoV-2) causing severe contagious respiratory tract infections presents a serious threat to public health worldwide. To date, there are no specific antiviral agents available for this disease, currently known as COVID-19. Therefore, genomic sequencing and therapeutic clinical trials are being conducted to develop effective antiviral agents. Several reports have investigated FDA-approved drugs as well as in silico virtual screening approaches such as molecular docking and modeling to find novel antiviral agents. Until now, antiparasitic drugs such as chloroquine have shown the most relevant results. Furthermore, there is an urgent need to understand the pathogenesis of this novel coronavirus, its transmission routes, surface survival and evolution in the environment. So far, the scientific community has indicated a possible transmission of COVID-19 via blood transfusion which is challenging in the case of asymptomatic individuals. Protocols for pathogen inactivation are also needed. In this paper, we reviewed recent findings about this life-threatening pandemic.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; pathogenicity; prevention; therapeutic advances

Year:  2020        PMID: 32512950     DOI: 10.3390/microorganisms8060850

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  2 in total

Review 1.  Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: lessons from the pandemic and preparing for future health crises.

Authors:  Natesh Singh; Bruno O Villoutreix
Journal:  Comput Struct Biotechnol J       Date:  2021-04-26       Impact factor: 7.271

2.  IoT-based analysis for controlling & spreading prediction of COVID-19 in Saudi Arabia.

Authors:  Sunil Kumar Sharma; Sameh S Ahmed
Journal:  Soft comput       Date:  2021-07-19       Impact factor: 3.643

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.